BACKGROUND Benign prostatic hyperplasia, the fourth most commonly diagnosed medical condition in the elderly, is a major underlying cause of lower urinary tract symptoms in men. Medical therapy is usually the first therapeutic option. Combination therapy is increasingly used for better symptom relief and outcome. METHODS We searched the literature using the MEDLINE database for the efficacy o...

Prostate cancer is among the most common causes of death from cancer in men, and accounts for 10% of all new male cancers worldwide. The diagnosis and treatment of prostate cancer place a substantial physical and emotional burden on patients and their families, and have considerable financial implications for healthcare providers and society. Given that the risk of prostate cancer continues to ...

Purpose: Previous studies have demonstrated a negative correlation between prostate volume and biopsy yield. By decreasing prostate volume, 5α-reductase inhibitors may enhance cancer detection, which may explain the greater detection of high-grade tumors in the finasteride arm of the Prostate Cancer Prevention Trial (PCPT). Materials and Methods: A mathematical model was constructed analyzing t...

Background Information: Currently alpha1-adrenoreceptor blockers with the combination of 5- alpha reductase inhibitors are widely used as first-line therapy to improve Lower urinary tract symptoms (LUTS) associated Benign Prostatic Hyperplasia (BPH). Aims And Objectives:The aim this study was evaluate Efficacy drug Silodosin and Dutasteride in patients mild severe symptoms. Materials Methods:Th...

PURPOSE Compare the efficacy and tolerability of dutasteride in combination with bicalutamide to bicalutamide monotherapy in the treatment of locally advanced and metastatic prostate cancer (PCa). METHODS One-hundred-fifty PCa patients with locally advanced or metastatic disease were prospectively enrolled and randomly assigned to receive either bicalutamide monotherapy 150 mg once daily (79 ...

Introduction. 5a-reductase inhibitors (5a-RIs), finasteride and dutasteride, have been approved for treatment of lower urinary tract symptoms, due to benign prostatic hyperplasia, with marked clinical efficacy. Finasteride is also approved for treatment of hair loss (androgenetic alopecia). Although the adverse side effects of these agents are thought to be minimal, the magnitude of adverse eff...